Jenell Stewart

Jenell Stewart

Auto-generated profile, based on publicly available information

Jenell Stewart

Hennepin Healthcare Research Institute, University of Minnesota , Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
JSJenell Stewart
Jenell Stewart
KOKevin Oware
Kevin Oware
DDDeborah Donnell
Deborah Donnell
LVLauren R. Violette
Lauren R. Violette
JOJosephine Odoyo
Josephine Odoyo
JBJared M. Baeten
Jared M. Baeten
Doxycycline postexposure prophylaxis (PEP) has been shown to prevent sexually transmitted infections (STIs) among cisgender men and transgender women, but data from trials involving cisgender women are lacking. We conducted a randomized, open-label trial comparing doxycycline PEP (doxycycline hyclate, 200 mg taken within 72 hours after condomless sex) with standard care among Kenyan women 18 to 30 years of age who were receiving preexposure prophylaxis against human immunodeficiency virus (HIV). The primary end point was any incident infection with Chlamydia trachomatis, Neisseria gonorrhoeae, or Treponema pallidum. Hair samples were collected quarterly for objective assessment of doxycycline use. A total of 449 participants underwent randomization; 224 were assigned to the doxycycline-PEP group and 225 to the standard-care group. Participants were followed quarterly over 12 months. A total of 109 incident STIs occurred (50 in the doxycycline-PEP group [25.1 per 100 person-years] and 59 in the standard-care group [29.0 per 100 person-years]), with no significant between-group difference in incidence (relative risk, 0.88; 95% confidence interval [CI], 0.60 to 1.29; P = 0.51). Among the 109 incident STIs, chlamydia accounted for 85 (78.0%) (35 in the doxycycline-PEP group and 50 in the standard-care group; relative risk, 0.73; 95% CI, 0.47 to 1.13). No serious adverse events were considered by the trial investigators to be related to doxycycline, and there were no incident HIV infections. Among 50 randomly selected participants in the doxycycline-PEP group, doxycycline was detected in 58 of 200 hair samples (29.0%). All N. gonorrhoeae-positive isolates were resistant to doxycycline. Among cisgender women, the incidence of STIs was not significantly lower with doxycycline PEP than with standard care. According to hair-sample analysis, the use of doxycycline PEP among those assigned to receive it was low. (Funded by the National Institutes of Health; dPEP ClinicalTrials.gov number, NCT04050540.).

14 February 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JSJenell Stewart
Jenell Stewart
MKMeighan L. Krows
Meighan L. Krows
TSTorin T. Schaafsma
Torin T. Schaafsma
KHKate B. Heller
Kate B. Heller
EBElizabeth R. Brown
Elizabeth R. Brown
RBRuanne V. Barnabas
Ruanne V. Barnabas
Enrollment of diverse populations in clinical trials is associated with more equitable opportunities and improved generalizability of results.1,2 Mistrust engendered by a long-standing track record of societal mistreatment experienced by Black, Hispanic, and Indigenous study participants is associated with underrepresentation of these groups in clinical trials.3 Issues such as proximity to trial sites, access to transportation, and time flexibility needed to participate are also associated with these disparities.2,4,5 Remote trials may be associated with reductions in some of these barriers.6

1 April 2020 in AIDS
Verified
Journal Article
Closed access
JSJenell Stewart
Jenell Stewart
EBElizabeth Bukusi
Elizabeth Bukusi
CCConnie Celum
Connie Celum
SDSinead Delany-Moretlwe
Sinead Delany-Moretlwe
JBJared M. Baeten
Jared M. Baeten

25 October 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JSJenell Stewart
Jenell Stewart
JBJared M. Baeten
Jared M. Baeten

16 June 2022 in Trials
Verified
Journal Article
Open access
PDF file
JSJenell Stewart
Jenell Stewart
EBElizabeth Bukusi
Elizabeth Bukusi
FSFredericka A. Sesay
Fredericka A. Sesay
KOKevin Oware
Kevin Oware
DDDeborah Donnell
Deborah Donnell
JBJared M. Baeten
Jared M. Baeten
Background: Women in Africa face disproportionate risk of human immunodeficiency virus (HIV) acquisition, accounting for more than half of new infections in Africa and similarly face a disproportionate burden of sexually transmitted infections (STIs). Very high STI prevalence is being observed globally, especially among people taking pre-exposure prophylaxis (PrEP) for HIV prevention. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender men who have sex with men (MSM) and transgender women who are taking PrEP in high-income settings. We designed and describe here the first open-label trial to determine the effectiveness of dPEP to reduce STI incidence among cisgender women. Methods: We are conducting an open-label 1:1 randomized trial of dPEP versus standard of care (STI screening and treatment and risk-reduction counseling without dPEP) among 446 Kenyan women aged ≥ 18 and ≤ 30 years old women taking PrEP. Women are followed for 12 months, with quarterly STI testing, treatment, and adherence counseling. The primary trial outcome will be the combined incidence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, compared between the randomized groups. We will also assess dPEP acceptability, tolerability, safety, impact on sexual behavior, adherence, and occurrence of antimicrobial resistance (AMR) in N. gonorrhoeae and C. trachomatis isolates. Finally, we will estimate cost per incident STI case and complications averted accounting for nonadherence and benefits relative AMR or side effects. Discussion: The results of this trial may have immediate implications for the global epidemic of STIs and sexual health. If effective, dPEP could put STI prevention into women’s hands. While dPEP may be able to prevent STIs, it carries important risks that could counter its benefits; global debate about the balance of these potential risks and benefits requires data to inform policy and implementation and our study aims to fill this gap. Trial registration: ClinicalTrials.gov NCT04050540.

12 September 2019 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JSJenell Do Stewart
Jenell Do Stewart
KSKathryn M. Stadeli
Kathryn M. Stadeli
MGMargaret L. Green
Margaret L. Green
LELisa Etter-Carlson
Lisa Etter-Carlson
EDElizabeth Dahl
Elizabeth Dahl
SDShireesha Dhanireddy
Shireesha Dhanireddy
This is a review of the first 50 patients attending a colocated continuity clinic with harm reduction services to women experiencing homelessness in north Seattle. Among those tested, patients had high rates of curable sexually transmitted infections (44%), injection opioid use (36%), transactional sex (69%), unintended pregnancy (10%), and human immunodeficiency virus infections (10%).